CMS(00867) self-developed innovative drug cardiac myosin inhibitor CMS-D003 obtained the drug clinical trial approval notice.

12/03/2025

GMT Eight

CMS (00867) announced that the innovative drug CMS-D003 capsule, which was independently developed by the group, received the drug clinical trial approval notification issued by the National Medical Products Administration (NMPA) of China on March 11, 2025, and received the drug clinical trial approval notification on March 12. NMPA has agreed for the group to conduct clinical trials in adult subjects with Chinese health and obstructive hypertrophic cardiomyopathy (oHCM) to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of CMS-D003.

German debt expansion disrupts European bond market: 10-year German bond yields expected to break 3% again after 18 months.

C WAN TONG YUAN (06966) issued a profit warning, expecting the annual attributable net profit and comprehensive income to decrease by approximately 40.3% to 46.0% to a total of 9.5 million to 10.5 million yuan.

Contact: contact@gmteight.com

CMS(00867) self-developed innovative drug cardiac myosin inhibitor CMS-D003 obtained the drug clinical trial approval notice.

RECOMMEND

US Stock Market Move | The weight loss drug Cagrisema's clinical trial results did not meet expectations. Novo Nordisk A/S Sponsored ADR Class B (NVO.US) dropped more than 5%.

Asiayang Group (01907) is planning an asset + cash transaction, and may take control of SINOHYTEC (688339.SH,02402) to expand its hydrogen industry chain layout.

Former US Treasury Secretary Mnuchin: Market reaction to Trump administration policies is excessive and unlikely to lead to economic recession.